Hwangbo, Haeun http://orcid.org/0000-0002-3687-4282
Patterson, Sarah C. http://orcid.org/0000-0002-1393-895X
Dai, Andy http://orcid.org/0000-0001-6149-3062
Plana, Deborah http://orcid.org/0000-0002-4218-1693
Palmer, Adam C. http://orcid.org/0000-0001-5028-7028
Funding for this research was provided by:
Korean Government Scholarship for Study Overseas
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32-GM135095, T32-GM007753)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F30-CA260780)
Article History
Received: 12 April 2023
Accepted: 11 October 2023
First Online: 16 November 2023
Competing interests
: A.C.P. has received consulting fees from AstraZeneca, Kymera and Merck, and research funding from Prelude Therapeutics. A.C.P. declares that these interests had no role in study design, analysis or decision to publish. The remaining authors declare no competing interests.